CO95 Matching-Adjusted Indirect Comparison (MAIC) in Previously Treated KRAS G12C-Mutated Advanced/Metastatic Non-Small Cell Lung Cancer (a/mNSCLC): Adagrasib Versus Sotorasib
A new class of therapies targeting KRAS G12C has emerged in a/mNSCLC, with FDA approvals of sotorasib (May-2021) and adagrasib (December-2022). Adagrasib was investigated in KRYSTAL-1, a Phase 2, single-arm trial in a/mNSCLC patients pre-treated with chemoimmunotherapy. A MAIC evaluated efficacy and safety of adagrasib in KRYSTAL-1 versus sotorasib in CodeBreaK100, a Phase 2 single-arm trial in a/mNSCLC patients pretreated with chemotherapy and/or immunotherapy, and CodeBreaK200, a Phase 3 randomized controlled trial (RCT) in a/mNSCLC patients pretreated with chemoimmunotherapy. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: W. Bouwmeester, M. Laurie, B. Korytowsky, M. Grevinga, C. Qian, A. Berardi, S. Gao, D. Stenehjem Source Type: research
CO96 Myelofibrosis Symptom Assessment Form Total Symptom Score (MFSAF TSS) v4.0: Measurement Properties from the Momentum Phase 3 Study
MFSAF v4.0, comprising 7 myelofibrosis (MF) symptom domains (fatigue, night sweats, pruritus, abdominal discomfort, pain under the left ribs, early satiety, bone pain) was developed by the Patient-Reported Outcome (PRO) Consortium MF Working Group to assess MF symptom severity. This post hoc analysis evaluated its measurement properties within the phase 3 MOMENTUM trial. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: C. Daskalopoulou, B. Gorsh, G. Dumi, S. Deheshi, C. Gwaltney, R. von Maltzahn, J. Paty, C. Ellis, J. Kawashima, B.J. Klencke, R. Mesa Source Type: research
CO97 Real-World Outcomes in Third-Line and Beyond (3L+) Small-Cell Lung Cancer (SCLC): A Systematic Literature Review (SLR)
SCLC is associated with limited treatment options and poor survival outcomes. This SLR aimed to understand the clinical unmet need of relapsed SCLC by reviewing real-world treatment outcomes of 3L+ SCLC in North American and European populations. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: F. Dirnberger, K. Appiah, B. Mayer, M. Rizzo, G. Suri Source Type: research
CO98 Health Outcomes and Cost-Effectiveness of Atezolizumab in Small Cell Lung Cancer
The aim of this study is to describe the effectiveness of atezolizumab in patients with previously untreated extensive-stage small cell lung cancer (ES-SCLC) and to analyze the cost-effectiveness of treatment in the context of a risk-sharing agreement (RSA) between hospital and pharmaceutical company. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: J.F. Marin Pozo, A. Plaza Arbeo, E. Marin Caba, V. Cao Vi ña, R. Contreras Collado, L. Gutierrez Lucena Source Type: research
CO99 Real-Life Effectiveness of Ibrutinib in Chronic Lymphocytic Leukemia
To analyze the effectiveness of ibrutinib in patients with Chronic Lymphocytic Leukemia (CLL) in a tertiary hospital, in order to have real-life effectiveness data to confirm the high efficacy found in the pivotal RESONATE-2 trial. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: L. Dom ínguez, M. Valera-Rubio, I. Carrión Madroñal Source Type: research
CO100 Regular Laboratory Checks for Ileostomy Patients After Surgery Are Not Performed Comprehensively, but Could Result in Better Health Outcomes
After ileostomy formation patients can face several problems in the first years. High output stoma (HOS) is one relevant condition likely resulting in electrolyte and acid imbalance due to high water, sodium and often magnesium depletion if not treated properly. It can lead to high costs in the health care system and a high burden for the patient. The aim of this study was to evaluate how laboratory checks are used as a screening tool in Germany. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: N. Surendranathan Source Type: research
CO101 Multiple Myeloma (MM) Refractory to Lenalidomide: A Systematic Literature Review (SLR) of Randomised Controlled Trials (RCTs)
Lenalidomide is increasingly used in early lines of therapy for patients with MM. Patients treated with lenalidomide, especially in maintenance settings, often experience relapse and become refractory. RCTs in second line and beyond (2L+) feature patients with varying lenalidomide exposure resulting in variable outcomes. Evaluation of 2L+ RCTs focusing on first-line lenalidomide exposure and subsequent impact on outcomes is valuable; understanding the evidence supporting therapies and associated outcomes in 2L+ lenalidomide-refractory patients is vital. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: S. McNamara, G. Kazeem, J.A. Carter, J. Bitetti, P.F. Wang Source Type: research
CO102 Physician Reported Treatment Attributes Considered in First-Line and Perceptions Around Bruton Tyrosine Kinase Inhibitor (BTKi) Treatments in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in the US
This study assesses physicians ’ perception and rationales for treatment choices in patients with CLL/SLL in the US. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: C. Jensen, Z. Ding, T. Greenwood, C. Kluth, I. Sanderson, N. Milloy, H. Mavani, W. Khan, Z.P. Qureshi Source Type: research
CO103 Modelled Impact of Nirsevimab for All Infants in Preventing Respiratory Syncytial Virus (RSV): Related Hospitalizations and Costs in the Brazilian Private Healthcare System
Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LTRI) in infants and children worldwide and poses a significant concern in Brazil. Palivizumab is covered by Health Insurance Companies for early preterm infants ( (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M. Falavigna, S.F. Watanabe, J. Santoro, K. Ribeiro, N. Schneider, M. Safadi, R.T. Stein, A. Kieffer, A. Tolardo Source Type: research
CO104 Identification and Selection of Biomarkers in Patient-Centric Treatment Management of Rare/Orphan Kidney Diseases: An Ongoing Research Project Aiming to Develop Personalized Treatment Algorithms
A patient-centric approach is key for managing rare/orphan kidney diseases. In this disease area, the identification and use of sensitive biomarkers, beyond initial diagnoses, is crucial for improving patient care [1]. This research study aims to identify suitable biomarkers for potential development of personalized treatment algorithms. By identifying and select biomarkers that can sensitively and rapidly detect meaningful changes of laboratory signs and patient-most burdensome clinical symptoms, the management of those already treated diseases could be significantly enhanced. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: D. Merante, H. Schou Source Type: research
CO105 A Retrospective Study Characterizing Age at Loss of Ambulation Among Patients With Friedreich Ataxia Using Health Administrative Claims Data in the United States
This study aimed to characterize the age at LOA among a cohort of patients with FA, using retrospective United States (US) claims data. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: A. Salvucci, C. Qian, L. Powell, D. Lynch, G. Vasco, K. Johnston, I. Tomazos Source Type: research
CO106 A Structured Expert Elicitation Exercise Conducted With UK Clinicians to Inform and Validate Inputs for a Cost-Effectiveness Analysis of FILSUVEZ ® Gel (Birch Bark Extract) in Epidermolysis Bullosa
Epidermolysis bullosa (EB) is a rare, chronic, genetic disorder characterised by skin fragility and blistering. Current standard of care (SoC), although heterogenous between patients, focuses on wound care, complication management, and improving quality of life. A structured expert elicitation (SEE) was conducted to inform key assumptions, validate data, and provide estimates for clinical and resource use parameters for a cost-effectiveness model (CEM), evaluating the impact of Filsuvez ® gel, licensed by EMA and MHRA, for treating partial thickness wounds in dystrophic EB (DEB) and junctional EB (JEB), in patients ≥6 m...
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: L. Stainer, S. Ryder, E. Carr, C. Collins, M. Arora, K. Tolley Source Type: research
CO107 Resource Use Associated with Alpelisib for the Treatment of Patients with PROS: A Modeling Approach
To model and assess the impact introduction of alpelisib (i.e., world with alpelisib) compared with current standard of care (SoC, i.e., world without alpelisib) would have on surgery rates for the treatment of adult and pediatric patients, 2 years of age and older, with severe manifestations of PIK3CA-related overgrowth spectrum (PROS) in France. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: N. Petrica, K. Cottard, P. Foss, S. Palladino, N. Yasar, J.F. Ricci Source Type: research
CO109 A Targeted Review of Pharmacological Therapies for the Treatment of Chronic Spontaneous Urticaria
Chronic spontaneous urticaria (CSU) is the sudden onset of hives and occasionally angioedema, lasting longer than six weeks. It is a condition that does not produce adequate treatment responses in>50% of patients prescribed H1-antihistamines. This review aimed to identify and categorize the outcomes and interventions used in clinical trials developing pharmaceutical therapies for effective treatment of CSU. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: J. Lawrence, O. Borecka, M. Alsawady, M. Sauca, K. Kallmes, S. Llewellyn Source Type: research
CO110 Systematic Literature Review and Network Meta-Analysis to Assess the Comparative Efficacy of Topical Fixed-Dose Combinations for Moderate to Severe Acne Vulgaris as Measured By Lesion Counts
The objective of this study is to conduct a systematic literature review (SLR) and network meta-analysis (NMA) to compare the efficacy of topical FDCs for reducing inflammatory lesion (ILs) and non-inflammatory lesion (NILs) count among patients with moderate to severe acne. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: J. Harper, H. Baldwin, B. Ghosh, S. Paul Choudhury, D. Rai, M.S. Aman, A.R. Choudhury, D. Dey, S. Dutta, S. Bhattacharyya, T. Lin, A.A. Dashputre, G. Jospeh, J. Tan Source Type: research
